What is the Avidity Biosciences Inc. stock price forecast?

Avidity Biosciences Inc. is currently trading at $12.37. View real-time AI analysis on Alpha Lenz.

What is Avidity Biosciences Inc. insider trading activity?

View the latest insider trading data for Avidity Biosciences Inc. on Alpha Lenz.

What is Avidity Biosciences Inc.'s P/E ratio?

Avidity Biosciences Inc.'s P/E ratio is -2.8.

Avidity Biosciences Inc.

NASDAQ · RNA

$12.37-0.06(-0.48%)Pre-market

Ask about Avidity Biosciences Inc.'s future dividend policy...

Alpha Chat Insight

“Avidity Biosciences Inc. trades at a P/E of -2.8 (undervalued) with modest ROE of -104.9%. 3Y revenue CAGR of 26.4% highlights clear growth momentum.”

Ask for details →

Company Overview

Avidity Biosciences Inc. is a biotechnology company focused on the development of innovative therapies for unmet medical needs. The primary aim of Avidity is to harness its proprietary Antibody Oligonucleotide Conjugates (AOCs) platform to create transformative healthcare solutions. This platform combines antibodies and oligonucleotides to precisely target and deliver therapeutic payloads to specific diseased cells, potentially advancing treatments for a range of genetic disorders. The company's research primarily impacts sectors such as rare disease treatment and genetic medicine, where precision and efficacy are critical. By leveraging its unique technology, Avidity Biosciences plays a significant role in the biotechnology landscape, fostering advancements that seek to alter the genetic disease treatment paradigm and improve patient outcomes globally.

CEOMs. Sarah Boyce

Websitehttps://www.aviditybiosciences.com

SectorHealthcare

IndustryBiotechnology

Employees391

Company Statistics

FY 2025

Profile

$211.70MMarket Cap

$18.62MRevenue

0.00Shares Out

391Employees

Margins

N/AGross

-410.84%EBITDA

-412.58%Operating

-412.64%Pre-Tax

-411.88%Net

Valuation

-2.76P/E

1.02P/B

11.37EV/Sales

0.71EV/EBITDA

-4.97P/FCF

Growth (CAGR)

26.38%Rev 3Yr

22.36%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-53.71%ROA

-104.92%ROE

-53.80%ROIC

Financial Health

$270.00MCash & Cash Equivalents

$-198.93MNet Debt

34.28%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Avidity Biosciences Inc. trades at a P/E of -2.8 (undervalued) with modest ROE of -104.9%. 3Y revenue CAGR of 26.4% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Avidity Biosciences Inc. (ticker: RNA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 391 employees. Market cap is $212M.

The current price is $12.37 with a P/E ratio of -2.76x and P/B of 1.02x.

ROE is -104.92% and operating margin is -412.58%. Annual revenue is $19M.